Literature DB >> 33750066

Chimeric Antigen Receptor-Modified Immune Effector Cell Therapies: Learning From the Present; Charting a Path to the Future.

Eric L Smith1, Renier J Brentjens2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33750066      PMCID: PMC8285986          DOI: 10.1097/PPO.0000000000000518

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


× No keyword cloud information.
  12 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Authors:  Noopur Raje; Jesus Berdeja; Yi Lin; David Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V Maus; Ashley Turka; Lyh-Ping Lam; Richard A Morgan; Kevin Friedman; Monica Massaro; Julie Wang; Greg Russotti; Zhihong Yang; Timothy Campbell; Kristen Hege; Fabio Petrocca; M Travis Quigley; Nikhil Munshi; James N Kochenderfer
Journal:  N Engl J Med       Date:  2019-05-02       Impact factor: 91.245

3.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.

Authors:  Eric L Smith; Kim Harrington; Mette Staehr; Reed Masakayan; Jon Jones; Thomas J Long; Khong Y Ng; Majid Ghoddusi; Terence J Purdon; Xiuyan Wang; Trevor Do; Minh Thu Pham; Jessica M Brown; Carlos Fernandez De Larrea; Eric Olson; Elizabeth Peguero; Pei Wang; Hong Liu; Yiyang Xu; Sarah C Garrett-Thomson; Steven C Almo; Hans-Guido Wendel; Isabelle Riviere; Cheng Liu; Blythe Sather; Renier J Brentjens
Journal:  Sci Transl Med       Date:  2019-03-27       Impact factor: 17.956

5.  Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.

Authors:  Renier J Brentjens; Eric L Smith; Carlos Fernández de Larrea; Mette Staehr; Andrea V Lopez; Khong Y Ng; Yunxin Chen; William D Godfrey; Terence J Purdon; Vladimir Ponomarev; Hans-Guido Wendel
Journal:  Blood Cancer Discov       Date:  2020-09

6.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Authors:  Michael Wang; Javier Munoz; Andre Goy; Frederick L Locke; Caron A Jacobson; Brian T Hill; John M Timmerman; Houston Holmes; Samantha Jaglowski; Ian W Flinn; Peter A McSweeney; David B Miklos; John M Pagel; Marie-Jose Kersten; Noel Milpied; Henry Fung; Max S Topp; Roch Houot; Amer Beitinjaneh; Weimin Peng; Lianqing Zheng; John M Rossi; Rajul K Jain; Arati V Rao; Patrick M Reagan
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

7.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

8.  Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

Authors:  Nirav N Shah; Bryon D Johnson; Dina Schneider; Fenlu Zhu; Aniko Szabo; Carolyn A Keever-Taylor; Winfried Krueger; Andrew A Worden; Michael J Kadan; Sharon Yim; Ashley Cunningham; Mehdi Hamadani; Timothy S Fenske; Boro Dropulić; Rimas Orentas; Parameswaran Hari
Journal:  Nat Med       Date:  2020-10-05       Impact factor: 53.440

9.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

10.  CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors:  Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.